Drug Profile

Research programme: NK cell therapeutics - Nkarta Therapeutics

Alternative Names: CAR19-NK programme

Latest Information Update: 28 Dec 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Nkarta Therapeutics
Class Immunotherapies; Natural killer cell therapies
Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Cancer

Most Recent Events

28 Dec 2022 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
28 Oct 2021 Nkarta Therapeutics in-licenses the Electroporation® technology and ExPERT™ platform from the MaxCyte
25 Mar 2021 Nkarta Therapeutics announces intention to submit IND to the US FDA for Cancer in the year 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com